Overview

A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the safety, tolerability and potential immune response to romosozumab following single subcutaneous (SC; injection under the skin) dose administration in healthy postmenopausal Japanese and non-Japanese women.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen